Beta Bionics面临证券欺诈集体诉讼，因其iLet FDA合规问题

after its inspection of Beta Bionics' iLet manufacturing

The complaint alleges these and other statements misled investors because, unknown to them, Beta Bionics concealed its receipt of thousands of iLet safety complaints

whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

the FDA published its January 28, 2026 WARNING LETTER to CEO Saint

Hagens Berman's team has secured more than $2.9 billion in this area of law.

Hagens Berman is investigating claims that Beta Bionics violated the federal securities laws

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.

The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower.